Alnylam Expands Genesis Pharma Partnership in Europe

Alnylam Pharmaceuticals widened its European commercial collaboration with Genesis Pharma, adding territories to a partnership that began in 2020. The companies did not disclose which countries or the financial terms of the expansion.

The deal keeps Alnylam’s sales-cost structure variable. Rather than building its own European field force, the biotech relies on regional partners to market its approved RNAi drugs: Onpattro for polyneuropathy, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1. Genesis Pharma already handled Onpattro and Givlaari in its original territory. The new geography puts those same products in front of more patients without adding fixed overhead.

The marginal revenue from the additional markets is likely modest near-term. Alnylam’s total 2024 revenue reached $1.8 billion, up 33% year over year. The bigger prize remains vutrisiran, a next-generation treatment for transthyretin amyloidosis with cardiomyopathy. The FDA decision date is March 2025. If approved, vutrisiran addresses a patient population far larger than the current indications. Genesis Pharma’s expanded territory gives Alnylam a ready launch infrastructure in Europe.

That setup explains the stock’s valuation premium. Alnylam trades at about 8 times trailing revenue, roughly double the median for biotech peers. The ALNY stock page shows an Alpha Score of 32 out of 100, a Weak rating. That score reflects the binary outcome tied to the FDA decision. A positive verdict could justify the multiple. A negative one would compress it sharply.

The sector readthrough is about commercial strategy. More RNAi companies are choosing regional partners over direct sales forces. Ionis Pharmaceuticals uses a similar model. The approach limits execution risk for a single product launch but also shares the revenue. For investors, the question is whether the partner model delivers higher risk-adjusted returns than a build-out approach – there is no universal answer.

Next catalyst on the calendar is the vutrisiran PDUFA date. After that, the next major data readout is for ALN-TTRsc02, a follow-on TTR silencer, expected in 2026. The expanded Genesis deal is one piece of the infrastructure needed to support those future launches.